Poster Sessions
Poster Session III
MOVEMENT DISORDERS: TICS, TREMOR, AND ATAXIA I
P3.014 Improving Tremor Detection
P3.001 Postmortem changes in
Bruce Musicus, Catherine Medlock, Alan Oppenheim, Randall Davis, Diana Apetauerova, Julie Leegwater-Kim, E Palmer, Dana Penney, William Souillard-Mandar
the motor vs. non-motor cerebellum of essential tremor —William Tate, Geoffrey Kelly, Phyllis Faust, Elan Louis
P3.002 Antisense FMR1 splice
variant and loss of AGG interruptions are predictors of Fragile X-associated tremor/ataxia syndrome (FXTAS) —
and Quantification with Automated Measurements of Stroke Energy —
MOVEMENT DISORDERS: DYSTONIA AND NEUROTOXIN THERAPIES
Padmaja Vittal, Shrikant Pandya, Kevin Sharp, Elizabeth Berry-Kravis, Lili Zhou, Bichum Ouyang, Jonathan Jackson BS, Deborah Hall
P3.015 Associations between
P3.003 A Congenital Form of
Cook, Beverly Snively, Kathleen Sweadner, Ihtsham Haq, Mark Stacy, Laurie Ozelius, Allison Brashear
Spinocerebellar Ataxia 13 : Insights from Three Biological Models —Swati Khare, Jerelyn Nick, Pedro Fernandez-Funez, Jada Lewis, Harry Nick, Michael Waters
P3.004 SYNE1 mutations cause adult onset autosomal recessive ataxia with retained reflexes in Brazilian patients — Maria Thereza Drumond Gama, Jose Luiz Pedroso, Orlando Barsottini, Anne Noreau, Gabrielle Houle, Alexandre Dionne-Laporte, Patrick Dion, Guy Rouleau
P3.005 Analysis of the Repeat Size
Distribution of over 82,000 Alleles in the Spinocerebellar Ataxias —Zhenyuan
P3.016 Clinical Relevance of
Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study —Zoltan Mari, Khashayar Dashtipour, Joseph Jankovic, Charles Adler, Marc Schwartz, Mitchell Brin
P3.017 Prospective, Single-blind, pilot trial of AbobotulinumtoxinA (AboA) in oromandibular dystonia (OMD) —Stewart Factor, Michael Silver, John Hanfelt, Elaine Sperin, Laura Scorr, Alan Freeman, H. Jinnah
P3.018 Improvement of Dystonia
P3.006 Frequency of tolerance and
P3.019 Long-term changes in
Almeida, Bryan Klassen, Anhar Hassan
Martin Nevrly, Petr Hlustik, Pavel Otruba, Pavel Hok, Michaela Kaiserova, Zbynek Tudos, Petr Kanovsky
P3.007 Spinocerebellar Ataxia Type 3—Characterization of a Portuguese Cohort —Joana Ribeiro, Ana Margarida Novo, Mario Sousa, Luciano Vieira, LuÌs Negr„o, Cristina Januario
P3.008 The pharmacokinetics of
SAGE-217 in Phase 1 SAD and MAD studies —Ethan Hoffman, Jeffrey Wald,
TUESDAY
Shane Raines, George Nomikos, Helen Colquhoun, Stephen Kanes
P3.009 Next-generation neuroactive steroid SAGE-217 in a multipleascending dose study —George Nomikos,
Helen Colquhoun, Michael Quirk, Shane Raines, James Doherty, Ethan Hoffman, Abdul Sankoh, Steve Kanes
P3.010 A blinded assessment of balance in patients with orthostatic tremor —Danish Bhatti, Rebecca Thompson, Yiwen Xia, Amy Hellman, L Schmaderer, Cindy Penke, Regan Iske, John Bertoni, Diego Torres-Russotto
P3.011 Childhood Tremor:
Electophysiological Evaluation and Clinical Correlates —Pattamon Panyakaew, Bennett Lavenstein, Mark Hallett
P3.012 Psychiatric comorbidities are
common in patients with Orthostatic Tremor —Danish Bhatti, Rebecca Thompson, Kalyan Malgireddy, Mark Fleisher, Daniel Murman, Diego Torres-Russotto
P3.013 Dentate nucleus neuronal
density: a postmortem study of essential tremor vs. control brains —Geoffrey Kelly, William Tate, Phyllis Faust, Elan Louis
Poster Session III Neighborhoods
F
E
P3.145–222
P3.111–144
P3.101–110A
Poster Discussion
C
P3.081–100
P3.020 Increased insula-putamen
connectivity in X-linked dystoniaparkinsonism —Anne Blood, Jeffrey Waugh, Thomas Munte, Marcus Heldmann, Aloysius Domingo, Christine Klein, Hans Breiter, Lillian Lee, Raymond Rosales, Norbert Bruggemann
P3.021 A Phase 2, Open-label,
dose-escalating study to evaluate the safety and preliminary efficacy of Daxibotulinumtoxina for injection (RT002) in isolated cervical dystonia. — Cynthia Comella, Allison Brashear, Joseph Jankovic, Atul Patel, Daniel Truong, Marian Evatt, Caroline Chung, Roman Rubio
P3.022 Determinants of Quality of Life in Cranial Dystonia —Laura Scorr, Stewart Factor, H. Jinnah
P3.023 Neural oscillatory activities of the motor thalamus in dystonia —Nagako Murase, Masao Matsuhashi, Yuji Maeda, Hidehiro Hirabayashi
P3.024 Correllation Between Time
Course, Level of Impact of Illness, Functionality, and Postural Measures of Patients with Cervical Dystonia —Livia Oliveira, Francisco Germiniani, Helio Afonso Teive, Sibele Mattozo, Roberta Werle, Ana Guimar„es
P3.025 Autonomic Nervous System Dysfunction in X-linked Dystonia Parkinsonism (XDP): Does it exist? — Melanie Leigh Supnet, Raymond Rosales
98 2017 AAN Annual Meeting Scientific Program
H
B
P3.251–328
P3.031–070 ePosters
P3.071–080
I
P3.329–412
Management by Specific Training of General Neurologist and Family Doctors —Maja Relja
sensorimotor cortical modulation in response to BoNT therapy in cervical dystonia. The functional MRI study. —
G
P3.223–250
D
brain structure and motor-related manifestations of rapid-onset dystoniaparkinsonism —Christopher Whitlow, Jared
Wang, Marc Meservey, Rebecca Moore, Julie Snyder, Nicholas Tiebout, Tara McNamara, Craig Hebert, Diem Doan, Michelle Alvayero, Sat Dev Batish, Michelle York, Joseph Higgins
ataxia following VIM thalamic deep brain stimulation in 113 essential tremor patients —Kamilia Nozile-Firth, Leonardo
Tuesday, April 25 8:30 a.m.—7:00 p.m.
A
P3.001–030 A: Movement Disorders B: Practice, Policy, and Ethics; Sleep; Cerebrovascular Disease and Interventional Neurology ePosters C: Aging and Dementia D: Cerebrovascular Disease and Interventional Neurology Poster Discussion E: Neuromuscular and Clinical Neurophysiology (EMG) F: Neuro-oncology; Neurocritical Care; Child Neurology G: Epilepsy/Clinical Neurophysiology (EEG) H: Cerebrovascular Disease and Interventional Neurology; Infectious Disease; Global Health I: MS and CNS Inflammatory Disease
P3.026 MYSTICOL: A multisite,
double-blind, randomized, placebocontrolled trial of rimabotulinumtoxinB for the treatment of sialorrhea in Parkinson’s disease (PD) and other neurological conditions —Stuart Isaacson,
Carlayne Jackson, Eric Molho, Richard Trosch, William Ondo, Thomas Clinch
P3.027 Safety and Efficacy of
High-Dose OnabotulinumtoxinA for PostStroke Upper Limb Spasticity: Results of a Double-Blind, Placebo-Controlled Trial —Atul Patel, Carolyn Geis, Katharine Alter, Grace Pan, Adele Thorpe, Lynn James, Rozalina Dimitrova
P3.028 Two Cases of Acute Allergic
Reaction Following Injection of Generic, Government-provided Botulinum Toxin a (GGP-BTA) for Hemifacial Spasm and Blepharospasm. —Laura Parolin, Francisco
Germiniani, Helio Afonso Teive, Rosana Scola, Conrado Borges
P3.029 IncobotulinumtoxinA in
Restless Legs Syndrome (RLS)—a Randomized Double Blind Cross Over Study —Duarte Machado, Diana Richardson, Bahman Jabbari
P3.030 Combined effects of rTMS and botulinum toxin therapy in benign essential blepharospasm —Wei Hu, Wissam Deeb, Joseph Legacy, Aparna Wagle-Shukla